INMT catalyzes the methylation and detoxification of the exogenous anticancer compounds, such as MSA and MSC, as well as the endogenous anticancer metabolites, such as Bis(7)-tacrine, resulting in PCa progression and CRPC growth and development (Fig. 7). The gene discussed is INMT; the disease is posterior cortical atrophy.